AlexanderISpiraMD

Oncology • Fairfax, VA

Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology, Sarcoma, Thoracic Cancer

Virginia Cancer Specialists

Join to view full profile

Dr. Spira is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Spira's full profile

Already have an account?

Office
8503 Arlington Blvd
Suite 400
Fairfax, VA 22031
Phone(703) 280-5390
Fax(703) 280-9596
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Medical Oncology, 2000 - 2003
University of Pennsylvania Health SystemResidency, Internal Medicine, 1997 - 2000
NYU School of MedicineClass of 1997

Certifications & Licensure

VA State Medical License 2003 - 2022
MD State Medical License 2000 - 2003
PA State Medical License 1998 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:Washington DC Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Top MD Consumers Checkbook

Clinical Trials

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 01Acoba J.,Attia S.,Bailey H.,Boles S.,Carney J.,Chow W.,D'amato G.,Dang L.,Davis L.,Druta M.,Ganjoo K.,Hainsworth J.,Hartner L.,Inst. S.C.,Jahan T.,Keedy V.,Kendall S.,Kim E.,Leu K.,Maki R.,Okuno S.,Partri...
Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Jul 01Aljumaily R.,Bordoni R.,Chu D.,Conkling P.,Edenfield J.,Ferrarotto R.,Gersten T.,Hart L.,Hussein M.,Jotte R.,Lammers P.,Nadler E.,Nikolinakos P.,Owonikoko T.,Richards D.,Rocha-lima C.,Schuster S.,Smith D....
Open Label Safety and Efficacy Study of CO-1686 in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI Start of enrollment: 2014 Apr 01Spira, A.,Morgensztern, D.,Gandara, D.,Spigel, D.
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Start of enrollment: 2014 Mar 01Spira, A.,Schrecengost, A.,Sanchez, C.,Colman, H.,Trusheim, J.,Choquette, K.,Sonty, K.,Vahanian, N.,Khleif, S.
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Ovarian Cancer Start of enrollment: 2014 Jan 01Spira, A.,Becerra, C.,Modiano, M.,Nanda, R.,Wilks, S.
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 01Novartis Pharmaceuticals
A Phase III Randomized, 3-arm, Open Label, Multicenter Study of LGX818 Plus MEK162 and LGX818 Monotherapy Compared With Vemurafenib in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma Start of enrollment: 2013 Sep 01Feun, L.G.,Cosgriff, T.M.,Packer, S.H.,Panella, T.J.,Garrison, M.,O'Day, S.J.,Niederman, T.M.,Wender, D.B.,Pecora, A.L.,Mazurczak, M.A.,Spira, A.I.,Beck, J.M.,Slater, D.,Starodub, A.N.,Hauke, R.J.,Tarhini...
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT Start of enrollment: 2013 Aug 01Groves, M.D.,Dhillon, N.,Santala, R.G.,Shimkus, B.J.,Thompson, M.A.,Cohn, A.L.,Hermann, R.C.,Larson, T.G.,Spigel, D.R.,Boyd, T.E.,Chawla, S.P.,Nikolinakos, P.G.,Taylor, M.H.,Blau, S.,Palchak, D.L.,Spitz, ...
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Jul 01Ezra Cohen, MD and Robert Ferris, MD, PhD
A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Double Start of enrollment: 2013 Jun 01Novartis Pharmaceuticals
A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Cisplatin in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) Start of enrollment: 2013 May 01Pietanza, M.C.,Hart, L.L.,Jotte, R.M.,Spira, A.I.,Spigel, D.R.,Gluck, W.L.
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 01Beck, J.M.,Wade, J.L.,Demetri, G.D.,Sohal, D.P.,Savin, M.A.,Buscema, J.,Dhillon, N.,Thambi, P.M.,Hurwitz, H.,Yardley, D.A.,Richards, D.A.,Nikolinakos, P.G.,Vaena, D.A.,Grilley-Olson, J.E.,Schwartzberg, L....
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2012 Oct 01Helen Ross, MD, Lyudmila Bazhenova, MD, Barbara Gitlitz, MD, David Bodkin, MD, Jonathan Goldman, MD, Merrill Shum, MD, Ross Camidge, Scott Gettinger, MD, Michael Guarino, Tarek Mekhail, Alberto Chiappori,...
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01Spira, A.,Cohn, A.L.,Ramirez, A.,O'Neil, B.,Becerra, C.H.,Peterson, C.,Smith, D.C.,Keller, D.,Richards, D.A.,Braiteh, F.S.,Cote, G.M.,Harsh, H.,Mier, J.W.,Kueber, J.,Poe, K.,Vitale, K.,Kossler, K.,Herrin,...
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01Langleben, A.,Spira, A.,Cohn, A.L.,Ramirez, A.,Adkins, A.,Biomedical, B.,Becerra, C.H.,Peterson, C.,Smith, D.,Jonker, D.,Richards, D.A.,Braiteh, F.S.,Currier, G.,Yoon, H.,Harsh, H.,Kueber, J.,Subramanian,...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC) Start of enrollment: 2010 Nov 01Agulnik, J.,Albert, I.,Alonso, G.,Aren, O.R.,Arriola, E.,Balint, B.,Barlesi, F.,Batura-Gabryel, H.K.,Bauman, J.E.,Belani, C.P.,Besse, B.,Bidoli, P.,Blackwell, E.A.,Boyd, T.E.,Brugger, W.,Buchanan, G.S.,Ca...
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Start of enrollment: 2010 Jun 01Borad, M., Eng, C., Lorente, G., Windsor, K., Dragovich, T., Brooks, D., Gorukanti, N., Rosen, P.J., Sigal, D.S., Garon, E., Yu, P., Haghighat, P., Belani, R., Baron, A., Cohn, A.L., Prete, S.D., Robbins,...
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer Medical Director
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Medical Director
A First-in-human Study Using BDC-1001 in Advanced HER2-Expressing Solid Tumors Amreen Husain, MD
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Arturo Molina, MD
Join now to see all

Publications & Presentations

PubMed

A phase 1b study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia
Amer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller, Prapti A. Patel, Alexander I. Spira, Michaela L. Tsai, Errin Samuelsz, Sandra L Silberm...> ;Clinical Cancer Research. 2020 Sep 30
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D. Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji Youn Han, Maximilian Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario Garcia Campelo, Dong...> ;Journal of Clinical Oncology. 2020 Aug 11
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
John D. Powderly, Alexander I. Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew W. Rasco, Bo Gao, Minna Tanner, Philippe Cassier, Anas Gazzah, Antoine Italian...> ;Clinical and Translational Science. 2020 Aug 8
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
Tap, W. D., Wagner, A. J., Schöffski, P., Martin-Broto, J., Krarup-Hansen, A., Ganjoo, K. N., Yen, C., Razak, A. R., Spira, A., Kawai, A., Le Cesne, A., Van Tine, B. A...> ;JAMA. 2020 Apr 8
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
Luis Paz-Ares, Alexander I. Spira, David Raben, David Planchard, Byoung Chul Cho, Mustafa Ozguroglu, Davey B. Daniel, A. Villegas, David Vicente, Rina Hui, S. Murakami...> ;Annals of Oncology. 2020 Mar 21
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escal...
O'Donnell, P. H., Arkenau, H. T., Sridhar, S. S., Ong, M., Drakaki, A., Spira, A. I., Zhang, J., Gordon, M. S., Degboe, A. N., Gupta, A. K., Mukhopadhyay, P., Huang, W...> ;Cancer. 2019 Oct 4
A review of canakinumab and its therapeutic potential for non-small cell lung cancer
Kara M. Schenk, Joshua E. Reuss, Karin Choquette, Alexander I. Spira> ;Anti-Cancer Drugs. 2019 Oct 1
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastilav Bahleda, Antoine Italiano, Cinta Hierro, Alain C. Mita, Andrés Cervantes, Nancy Chan, Mark M. Awad, Emiliano Calvo, Victor Moreno, Ramaswamy Govindan, Alexand...> ;Clinical Cancer Research. 2019 Aug 15
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.
Morgensztern, D., Rose, M., Waqar, S. N., Morris, J., C, P., Reid, T., Brzezniak, C. E., Zeman, K. G., Padmanabhan, A., Hirth, J., Spira, A. I., Trepel, J. B., Padda, ...> ;British journal of cancer. 2019 Jun 25
Detection of NRG1 Gene Fusions in Solid Tumors.
Jonna, S., Feldman, R. A., Swensen, J., Gatalica, Z., Korn, W. M., Borghaei, H., C, P., Nieva, J. J., Spira, A. I., Vanderwalde, A. M., Wozniak, A. J., Kim, E. S., Liu...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Apr 17
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.
Brendan Bulik-Sullivan, Jennifer Busby, Christine D. Palmer, Matthew J. Davis, Tyler Murphy, Andrew Clark, Michele Busby, Fujiko Duke, Aaron Yang, Lauren Young, Noelle...> ;Nature Biotechnology. 2019 Jan 1
Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.
Michelle A. Ojemuyiwa, Karen Zeman, Alexander I. Spira, Bryan Oronsky, Carolyn M. Ray, Jane B. Trepel, Min-Jung Lee, Ifeyinwa Onyiuke, Christina Brzezniak> ;Clinical Case Reports. 2018 Nov 5
Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Base...
David A. Barbie, Alexander I. Spira, Karen Kelly, Rita Humeniuk, Jun Kawashima, Shengchun Kong, Marianna Koczywas> ;Clinical Lung Cancer. 2018 Nov 1
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
Marcin Kowanetz, Wei Zou, Scott N. Gettinger, Hartmut Koeppen, Mark M. Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David...> ;Proceedings of the National Academy of Sciences of the United States of America. 2018 Oct 23
Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
Helman, E., Nguyen, M., Karlovich, C. A., Despain, D., Choquette, A. K., Spira, A. I., Yu, H. A., Camidge, D. R., Harding, T. C., Lanman, R. B., Simmons, A. D.> ;Clinical lung cancer. 2018 Oct 4
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D. Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji Youn Han, Jong Seok Lee, Maximilian Hochmair, Jacky Yu-Chung Li, Gee Chen Chang, Ki Hyeong Lee, C...> ;The New England Journal of Medicine. 2018 Sep 25
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion.
Farago, A. F., Taylor, M. S., Doebele, R. C., Zhu, V. W., Kummar, S., Spira, A. I., Boyle, T. A., Haura, E. B., Arcila, M. E., Benayed, R., Aisner, D. L., Horick, N. K...> ;JCO precision oncology. 2018 Sep 15
2 citations
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advance...
David R. Spigel, Craig W. Reynolds, David M. Waterhouse, Edward B. Garon, Jason C. Chandler, Sunil Babu, Paul Thurmes, Alexander I. Spira, Robert M. Jotte, Jin Zhu, We...> ;Journal of Thoracic Oncology. 2018 May 1
Signature program: a platform of basket trials.
Eric Daniel Slosberg, Barinder P. Kang, Julio Peguero, Matthew H. Taylor, Todd Michael Bauer, Donald A. Berry, Fadi Braiteh, Alexander I. Spira, Funda Meric-Bernstam, ...> ;Oncotarget. 2018 Apr 20
9 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guide...
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, P...> ;Journal of Clinical Oncology. 2018 Feb 14
2 citations
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.
Yu, H. A., Spira, A. I., Horn, L., Weiss, J., West, H., Giaccone, G., Evans, T. L., Kelly, R. J., Desai, B. B., Krivoshik, A., Moran, D., Poondru, S., Jie, F., Aoyama,...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Sep 29
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Mark R. Litzow, Maria R. Baer, David F. Claxton, Harry P. Erba, Stan Gill, Stuart L. Goldber...> ;Lancet Oncology. 2017 Aug 1
Efficacy and Safety Results of the Afatinib Expanded Access Program.
Kim, E. S., Halmos, B., Kohut, I. F., Patel, T., Rostorfer, R. D., Spira, A. I., Cseh, A., McKay, J., Wallenstein, G., Mileham, K. F.> ;Oncology and therapy. 2017 Jul 7
Innovations in Clinical Trial Design in the Era of Molecular Profiling.
Wulfkuhle, J. D., Spira, A., Edmiston, K. H., Petricoin, E. F.> ;Methods in molecular biology (Clifton, N.J.). 2017 May 16
6 citations
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Bryan Oronsky, Carolyn M. Ray, Alexander I. Spira, Jane B. Trepel, Corey A. Carter, Hope M. Cottrill> ;Medical Oncology. 2017 Apr 25
Join now to see all

Abstracts/Posters

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

The Impact of Immunotherapy on a Community Practice. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 2)
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Authored Content

Exploring Why Testing in Lung Cancer Is Important to Treatment DecisionsDecember 2020
Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018

Press Mentions

Clinical Challenges: Second-Line Treatment for NSCLC After Failure of ImmunotherapyJune 29, 2020 09:33
Advanced Soft Tissue Sarcomas: Dox + Olaratumab vs. Dox + PBOJune 02, 2019 23:10
Augmedix’s EHR Documentation Platform Enters Innovative Pilot with Award-Winning iKnowMed Oncology EHRDecember 06, 2018 17:38
Join now to see all